2017 - Fellow of the Australian Academy of Health and Medical Science
His scientific interests lie mostly in Melanoma, Cancer research, Pathology, Internal medicine and Oncology. His Melanoma research focuses on Cutaneous melanoma in particular. His work is dedicated to discovering how Cancer research, MAPK/ERK pathway are connected with Targeted therapy and other disciplines.
Richard A. Scolyer interconnects Nevus and Confidence interval in the investigation of issues within Pathology. In his work, Radiation therapy is strongly intertwined with Carcinoma, which is a subfield of Oncology. His Cancer study combines topics in areas such as Survival rate and V600E.
Richard A. Scolyer focuses on Melanoma, Pathology, Cancer research, Internal medicine and Oncology. Particularly relevant to Cutaneous melanoma is his body of work in Melanoma. His biological study spans a wide range of topics, including Dermatology and Nevus.
His Cancer research research is multidisciplinary, incorporating perspectives in Cell, Mutation, Immune system, Immunology and Neuroblastoma RAS viral oncogene homolog. His Oncology research incorporates themes from Stage, Primary tumor, Disease and Hazard ratio. His research integrates issues of Sentinel lymph node, Surgery and Sentinel node in his study of Biopsy.
Melanoma, Internal medicine, Cancer research, Oncology and Cutaneous melanoma are his primary areas of study. His studies deal with areas such as Cancer, Metastasis, Immunotherapy, Breslow Thickness and Biopsy as well as Melanoma. His Cancer research study also includes fields such as
As part of the same scientific family, Richard A. Scolyer usually focuses on Oncology, concentrating on Lymph node and intersecting with Stage. His research in Cutaneous melanoma intersects with topics in Mutation, Primary tumor, Proportional hazards model and Cohort. Within one scientific family, he focuses on topics pertaining to Nivolumab under Ipilimumab, and may sometimes address concerns connected to Stage III melanoma.
The scientist’s investigation covers issues in Melanoma, Internal medicine, Cancer research, Oncology and Cancer. Cutaneous melanoma is the focus of his Melanoma research. His Cutaneous melanoma research includes themes of Breslow Thickness, Nevus, Benign melanocytic nevus and Sentinel node.
His Cancer research research is multidisciplinary, incorporating elements of Cancer cell, Mutation, Gene mutation, Tumor-infiltrating lymphocytes and Chromatin. His Oncology study integrates concerns from other disciplines, such as Discontinuation, Cytokine, Gene, Hazard ratio and Biomarker. In his study, which falls under the umbrella issue of Cancer, Seer program is strongly linked to General surgery.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Genomic Classification of Cutaneous Melanoma
Rehan Akbani;Kadir C. Akdemir;B. Arman Aksoy;Monique Albert.
Pan-cancer analysis of whole genomes
Peter J. Campbell;Gad Getz;Jan O. Korbel;Joshua M. Stuart.
Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual.
Jeffrey E. Gershenwald;Richard A. Scolyer;Kenneth R. Hess;Vernon K. Sondak.
CA: A Cancer Journal for Clinicians (2017)
Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic Melanoma
Georgina V. Long;Alexander M. Menzies;Adnan M. Nagrial;Lauren E. Haydu.
Journal of Clinical Oncology (2011)
Loss of 5-Hydroxymethylcytosine Is an Epigenetic Hallmark of Melanoma
Christine Guo Lian;Yufei Xu;Craig Ceol;Craig Ceol;Feizhen Wu.
Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance.
Hubing Shi;Gatien Moriceau;Xiangju Kong;Mi Kyung Lee.
Nature Communications (2012)
Whole-genome landscapes of major melanoma subtypes
Nicholas K. Hayward;Nicholas K. Hayward;James S. Wilmott;Nicola Waddell;Nicola Waddell;Peter A. Johansson.
Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma
James Samuel Wilmott;Georgina V. Long;Julie R. Howle;Julie R. Howle;Lauren E. Haydu.
Clinical Cancer Research (2012)
Tumor-Infiltrating Lymphocyte Grade Is an Independent Predictor of Sentinel Lymph Node Status and Survival in Patients With Cutaneous Melanoma
Farhad Azimi;Richard A. Scolyer;Pavlina Rumcheva;Marc Moncrieff.
Journal of Clinical Oncology (2012)
Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study
Georgina V Long;Victoria Atkinson;Serigne Lo;Shahneen Sandhu.
Lancet Oncology (2018)
(Impact Factor: 5.335)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: